Albert David Ltd. (BSE: 524075) is a Kolkata, West Bengal-based company in the Pharmaceuticals industry. With a market capitalisation of ₹451 Cr, it ranks #2,068 by market cap among the 6,197 Indian listed companies on FinBizNet, and #28 of 63 in Pharmaceuticals. At ₹782.10 (as of 16 Nov 2026), the share price is 16.1% below its 52-week high of ₹931.85 and 34.9% above its 52-week low of ₹579.90. The share price is down 9.9% over one year and down 2.1% over three months.
| Current Price | ₹782.10 |
|---|---|
| Market Cap | ₹451 Cr |
| BSE Code | 524075 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -0.38% |
| Return on Assets | -0.49% |
| 52-Week Range | ₹579.90 – ₹931.85 |
| 1-Year Price Change | -9.9% |
| 3-Month Price Change | -2.1% |
| Beta (1Y) | 0.63 |
| Dividend Yield | 0.63% |
| Headquarters | Kolkata, West Bengal |
| Website | www.albertdavidindia.com |
| Revenue | ₹101 Cr |
|---|---|
| Net Profit | ₹3 Cr |
| Net Margin | 2.9% |
| EPS (Basic) | ₹5.05 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Albert David Ltd. reported revenue of ₹101 Cr in Q2 FY27, up 15.6% from ₹87 Cr in Q2 FY26 and down 0.5% from ₹101 Cr in Q1 FY27. It posted a net profit of ₹3 Cr for the quarter, against a net loss of ₹3 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹71 Cr (Q1 FY26) to ₹101 Cr (Q1 FY27). The company reported a net loss in 3 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹101 Cr | ₹3 Cr | 2.9% |
| Q1 FY27 | ₹101 Cr | ₹32 Cr | 31.6% |
| Q4 FY26 | ₹86 Cr | −₹21 Cr | −25.0% |
| Q3 FY26 | ₹90 Cr | ₹15 Cr | 17.0% |
| Q2 FY26 | ₹87 Cr | −₹3 Cr | −3.8% |
| Q1 FY26 | ₹71 Cr | ₹8 Cr | 11.3% |
| Q4 FY25 | ₹75 Cr | −₹10 Cr | −13.8% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 62.24% of Albert David Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 64.0% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India and internationally. It offers formulations for parenterals, oral/enterals, topical agents, aerosol, gynecology therapy, orthopedic, and vision care products. Albert David Limited was incorporated in 1938 and is headquartered in Kolkata, India.
1. Pharmaceuticals-This segment manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs.
1. Manufacturing of Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Albert David Ltd. | ₹451 Cr | n/m | -0.38% | ₹101 Cr | -9.9% |
Listed by market capitalisation. Ratios are shown for context only.
Albert David Ltd. is trading at ₹782.10, with a market capitalisation of ₹451 Cr.
Albert David Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Albert David Ltd. has a return on equity of -0.38%.
Albert David Ltd. is listed on the BSE under the scrip code 524075.
Albert David Ltd.'s share price is down 9.9% over one year and down 2.1% over three months. Its 52-week range is ₹579.90 to ₹931.85.
In Q2 FY27, Albert David Ltd. reported revenue of ₹101 Cr and net profit of ₹3 Cr, with basic EPS of ₹5.05 (standalone, parsed from the company's exchange filing).
Albert David Ltd. reported revenue of ₹101 Cr in Q2 FY27, up 15.6% from ₹87 Cr in Q2 FY26 and down 0.5% from ₹101 Cr in Q1 FY27.
Promoters held 62.24% of Albert David Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.